Patent intelligence · US
US 9795592
Pharmaceutical formulations of vildagliptin
Pharmaceutical formulations of vildagliptin
Patent details — US 9795592
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 24, 2017
- Expiration
- Oct 19, 2037
- Claims
- 16
- CPC classes
- A61K, A61K31/40, A61K9/2009, A61K9/2013
Quick answer
US 9795592 (Pharmaceutical formulations of vildagliptin) is held by SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI. Status: granted. Granted Oct 24, 2017. Expires Oct 19, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/40, A61K9/2009, A61K9/2013, A61K9/2027, A61K9/2054
More from SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 9795592?
US 9795592 (Pharmaceutical formulations of vildagliptin) is held by SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI. Status: granted. Granted Oct 24, 2017. Expires Oct 19, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9795592?
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 9795592 expire?
Our index shows an expiration date of Oct 19, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.